FDA Grants Orphan Drug Designation to March Biosciences for T-Cell Lymphoma
By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...
Pharmabiz1d
March Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma
Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...
Targeted Oncology2d
FDA Grants Orphan Drug Designation to MB-105 for R/R T-Cell Lymphoma
MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...
March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma
Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (March Bio), an emerging clinical stage biotechnology company committed to combating ...
Bay Area biotech firm IGM Biosciences, once worth billions, guts staff with 73% layoff
IGM Biosciences is laying off 100 workers as it shuts down two research projects, causing the Mountain View company's stock to tank.
bovnews3d
Why Did Sagimet Biosciences Inc (SGMT) Stock Rise 10.00% to $4.62?
Sagimet Biosciences Inc (SGMT) stock saw a modest uptick, ending the day at $4.62 which represents a slight increase of $0.42 or 10.00% from the prior close of $4.2. The stock opened at $4.29 and ...
bovnews8d
Why Ventyx Biosciences Inc (VTYX) Stock is Currently -1.57% Off from Its 20-Day SMA?
Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.16 which represents a slight increase of $0.08 or 3.85% from the prior close of $2.08. The stock opened at $2.05 and ...